Group 1 - The core viewpoint of the article highlights that Guoen Technology (02768) experienced a decline of over 5% on its second day of trading, closing at HKD 37.94 with a transaction volume of HKD 117 million [1] - Guoen Technology officially listed on the Hong Kong Stock Exchange on February 4 and was included in the Hong Kong Stock Connect on its first trading day [1] - The company specializes in chemical new materials and upstream and downstream products of gelatin and collagen, serving both the chemical and health industries [1] Group 2 - According to the prospectus, Guoen Technology is the second-largest organic polymer modified materials and organic polymer composite materials company in China by sales revenue, holding a market share of 2.5% as of 2024 [1]

Core Viewpoint - Guoen Technology (02768) experienced a decline of over 5% on its second day of trading, closing at HKD 37.94 with a transaction volume of HKD 117 million [1] Group 1: Company Overview - Guoen Technology officially listed on the Hong Kong Stock Exchange on February 4 and was included in the Stock Connect on its first trading day [1] - The company specializes in chemical new materials and upstream and downstream products of gelatin and collagen, serving both the chemical and health industries [1] - Guoen Technology is engaged in the research, development, production, and sales of products for industrial and commercial use [1] Group 2: Market Position - According to Frost & Sullivan, Guoen Technology is the second-largest organic polymer modified materials and organic polymer composite materials company in China by sales revenue, holding a market share of 2.5% as of 2024 [1]

Group 1 - The core viewpoint of the article highlights the successful listing of Qingdao Guoen Technology Co., Ltd. on the Hong Kong Stock Exchange, marking it as the first company in Shandong Province to achieve A+H dual listing in 2026 [2] - On its first trading day, Guoen Technology's stock surged by 37.06%, reaching a market capitalization of 14.864 billion HKD, indicating strong market performance [2] - The company specializes in chemical new materials and health sectors, focusing on upstream and downstream products such as gelatin and collagen, positioning itself as a key supplier in these industries [2] Group 2 - The successful listing of Guoen Technology contributes to the growth of the Qingdao Stock Exchange, with the total number of listed companies in Qingdao reaching 21 and IPO fundraising exceeding 13 billion CNY [3] - There are currently 6 companies awaiting approval for listing on the Hong Kong Stock Exchange and 2 companies have announced plans for A+H listings [3] - The municipal financial office plans to deepen cooperation with the Hong Kong Stock Exchange to support more companies in accessing global capital and enhancing the quality of the real economy [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 Qingdao Gon Technology Co., Ltd. 青島國恩科技股份有限公司 本 公 告 乃 由 青 島 國 恩 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有限公司證券上市規則第13.10B條 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 發 佈 之《青 島 國 恩 科 技 股 份 有 限 公 司 關 於 控 股 股 東 及 一 致 行 動 人 權 益 變 動 的 提 示 性 公 告》，僅 供 參 閱。 承董事會命 青島國恩科技股份有限公司 董事長兼執行董事 王愛國先生 香 港，2026年2月4日 截 至 本 公 告 日 期，本 公 司 的 執 行 董 事 為 王 愛 國 先 生、李 宗 好 先 生、李 慧 穎 女 士 以 及 韓 博 先 生；及 本 公 司 ...

Qingdao Gon Technology Co., Ltd. 青島國恩科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任 何 損 失 承 擔 任 何 責 任。 （股 份 代 號：2768） 海外監管公告 王愛國先生 香 港，2026年2月4日 截 至 本 公 告 日 期，本 公 司 的 執 行 董 事 為 王 愛 國 先 生、李 宗 好 先 生、李 慧 穎 女 士 以 及 韓 博 先 生；及 本 公 司 的 獨 立 非 執 行 董 事 為 王 亞 平 先 生、孫 建 強 先 生 以 及 項 婷 女 士。 青岛国恩科技股份有限公司 简式权益变动报告书 | 公司名称 | 青岛国恩科技股份有限公司 | | --- | --- | | 上市地点 | 股） 深圳证券交易所（A 股）、香港联合交易所有限公司（H | | 股票简称 | 国 ...

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. (referred to as "Guoen Technology") has successfully listed on the Hong Kong Stock Exchange, raising a total of HKD 1.08 billion through the issuance of 30 million shares at an offering price of HKD 36 per share [1][3]. Group 1: Company Overview - Guoen Technology specializes in chemical new materials and upstream and downstream products such as gelatin and collagen, serving the chemical and health industries [4]. - The company has a diverse customer base, including manufacturers in the automotive, new energy, and home appliance sectors, as well as pharmaceutical manufacturers in the health sector [4]. - Guoen Technology has made several strategic acquisitions to enhance its vertical integration and expand its presence in the health industry, including the acquisition of Yiqing Bio and Dongbao Bio [4]. Group 2: Financial Performance - The company's revenue for 2022, 2023, and 2024 is projected to be RMB 134 billion, RMB 174.4 billion, and RMB 191.9 billion, respectively, with net profits of RMB 7.2 billion, RMB 5.4 billion, and RMB 7.2 billion during the same periods [5][6]. - For the first ten months of the 2025 fiscal year, Guoen Technology reported revenue of RMB 174.4 billion and a net profit of RMB 7.21 billion [7]. Group 3: Shareholder Structure - The controlling shareholders of Guoen Technology are Wang Aiguo and his wife, holding 56.6% of the shares [8]. - Wang Aiguo, the founder and chairman, holds 46.45% of the shares, while other significant shareholders include Qingdao Century Star Hao Investment Co., Ltd. and Xu Bo [15][16].

Core Viewpoint - Qingdao Guoen Technology Co., Ltd. (referred to as "Guoen Technology") has successfully listed on the Hong Kong Stock Exchange, closing at HKD 40.16 with an increase of 11.56% on the first day of trading [1]. Group 1: Company Overview - Guoen Technology specializes in the supply of new chemical materials and upstream and downstream products of gelatin and collagen [1]. - The company issued a total of 30,000,000 shares, with 3,000,000 shares available for public offering in Hong Kong and 27,000,000 shares for international offering [2]. Group 2: Financial Details - The final offering price was set at HKD 36.00, resulting in total proceeds of HKD 1,080.0 million. After deducting estimated listing expenses of HKD 79.6 million, the net proceeds amounted to HKD 1,000.4 million [2][3]. - The net proceeds from the global offering will be used for establishing a new production base in Thailand to expand capacity, enhancing the production capacity of the new base in Yixing, China, and general corporate purposes [3]. Group 3: Investor Information - Key cornerstone investors include Liguan Investment Co., Ltd., SLD International Enterprises Limited, and several others, with varying percentages of share allocation [5][6].

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Sinopec Oilfield Services leading in premium rates, while CATL, China Merchants Bank, and WuXi AppTec are at the bottom of the list [1][2]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 351.07% - Sinopec Oilfield Services (01033) with a premium rate of 303.37% [2] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -12.99% - China Merchants Bank (03968) with a premium rate of -1.83% - WuXi AppTec (02359) with a premium rate of 3.29% [2] Deviation Values - The top three shares by deviation value are: - Guoen Technology (02768) with a deviation value of 64.57% - Goldwind Technology (02208) with a deviation value of 30.74% - Sinopec Oilfield Services (01033) with a deviation value of 27.72% [1][2] - The bottom three shares by deviation value are: - Junda Co., Ltd. (02865) with a deviation value of -49.44% - Zhejiang Shibao (01057) with a deviation value of -46.76% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -34.58% [1][3].

Market Overview - The US stock market experienced a decline, with the Chinese concept index dropping by 0.94%. The Hang Seng Index fell by 110.27 points, a decrease of 0.41%, closing at 26,724.50 points, while the Hang Seng Tech Index dropped by 120.19 points, down 2.20%, reaching a new low since mid-July 2025 [1] - Technology stocks, particularly those considered riskier, continued to decline, with Tencent falling nearly 4% after restrictions on its "Yuanbao Red Packet" link by WeChat. Other major players like Baidu, Meituan, and Xiaomi also saw declines of over 2%, while Bilibili dropped nearly 5% [1] - Chip stocks faced significant losses, with Shanghai Fudan down nearly 9%, Huahong Semiconductor down over 5%, and SMIC down nearly 3% [1] - The coal sector showed strength, with Feishang No Smoke Coal rising over 33%. Real estate stocks also performed well, with Sunac China up over 7% and China Resources Land up nearly 4% [1] Corporate Developments - In the technology sector, InnoCare successfully completed a significant design integration for AI hardware with Google, establishing a solid foundation in the AI hardware market [1] - Enoch Intelligent received a milestone payment of HKD 39 million from Menarini, marking a significant step in its pharmaceutical technology research [1] - Capital investment firm Shumeng Capital signed a contract worth USD 3 million with a Macau distributor, expanding its business footprint [1] Pharmaceutical Industry Highlights - Youzhiyou Biotech's M701 received FDA IND approval for a novel therapy targeting malignant pleural effusion, marking a new phase in international clinical development [2] - Xiansheng Pharmaceutical received a milestone payment of USD 40 million from AbbVie for the overseas licensing option agreement for SIM0500, highlighting its competitiveness in the international pharmaceutical market [2] - Kangfang Biotech granted exclusive commercialization rights for Yixinning® to Jichuan Pharmaceutical, resulting in significant licensing fees and milestone payments [2] - Federal Pharmaceuticals' UBT251 injection received implied clinical trial approval for a new indication, providing new treatment options for patients [2] Food Industry Performance - Nissin Foods reported strong performance in its China business segment, with revenue reaching JPY 54.948 billion, a year-on-year increase of 2.7%, and core operating profit of JPY 5.859 billion, up 9.3% [2] Capital Market Insights - Guotai Junan International noted a market shift from "liquidity-driven" to "profit-driven" dynamics, suggesting a focus on fundamental analysis rather than speculative trading [4] - CITIC Securities observed significant adjustments in Hong Kong stock earnings expectations, predicting a continuation of the spring market rally with large-cap stocks outperforming [4] - Huatai Securities indicated that the current market sentiment has shifted to optimism, suggesting a focus on companies with earnings certainty and potential for growth in technology and cyclical sectors [5] - Guoyuan International highlighted that Hong Kong stocks may continue to outperform US stocks due to favorable conditions for non-US assets and the potential recovery of domestic demand [5]

Group 1 - All newly listed stocks in the Hong Kong market this year have seen an increase on their first trading day, with no stocks experiencing a decline [2] - Guoen Technology (02768.HK) officially listed on the Hong Kong Stock Exchange on February 4, with a significant opening increase of 27%, reaching a price of HKD 45.72 [2] - The public offering of Guoen Technology was oversubscribed by 2,251.85 times, with 3 million shares available for public subscription, accounting for 10% of the total offering [3] Group 2 - The international placement of Guoen Technology was oversubscribed by 10.03 times, with 27 million shares allocated, representing 90% of the total offering [3] - The final offer price for Guoen Technology was set at HKD 36.00 per share, which is in the lower-middle range of the pricing range (HKD 34.00 to HKD 42.00), raising approximately HKD 1 billion in net proceeds [3] - Guoen Technology specializes in chemical new materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] Group 3 - Guoen Technology operates within the large chemical industry, covering the entire value chain of chemical new materials, including upstream green petrochemical materials and downstream applications in electronics, automotive, and renewable energy sectors [4] - The company has a complete layout from collagen and derivative raw materials to end products, gradually becoming a comprehensive group in the health sector [4] - For the fiscal years 2022 to 2025, Guoen Technology's revenues are projected to be RMB 13.406 billion, RMB 17.439 billion, RMB 19.188 billion, and RMB 17.444 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, RMB 0.721 billion, and RMB 0.721 billion [4]